Connect with us

Hi, what are you looking for?

Jewish Business News


Teva : anti-depressant Armodafinil (NUVIGIL) trial fails

Results from Final Phase III Study of in Patients with Major Depression Associated with Bipolar I Disorder failed to show that it was more effective than a placebo.

Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at
Thank you.


Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced top-line results of its final Phase III clinical study for armodafinil (NUVIGIL) as adjunct therapy in adults with major depression associated with bipolar I disorder.

The current study was the third Phase III clinical trial, all of which Teva said demonstrated improvements in patient response. It added that on the basis of an evaluation of the totality of results, it will not proceed with regulatory filings for the drug. “There is no material impact to the company, ” said Teva.

“While this study demonstrated a numerical improvement, we are disappointed that armodafinil did not reach statistical significance, ” said Teva CSO and president Global R&D Dr. Michael Hayden. “We will continue to focus on our current Nuvigil indications”.

The US Food and Drug Administration (FDA) approved Nuvigil a prescription medicine to improve wakefulness in adults who experience excessive sleepiness (ES) due to obstructive sleep apnea (OSA), shift work disorder (SWD), or narcolepsy. NUVIGIL is not approved for use in treating major depression associated with bipolar I disorder.




You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...


The Movie The Professional is what made Natalie Portman a Lolita.


After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.